Trade Bristol Myers ^BMY

BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial

Citizens Financial Group Inc. RI Buys 44,768 Shares of Bristol Myers Squibb Company $BMY

Tempus AI's (TEM) Buy Rating Reiterated at Needham & Company LLC - Zolmax

Bristol Myers Squibb Company $BMY Stake Lessened by Lantern Wealth Advisors LLC - Zolmax

Bristol Myers Squibb Company $BMY Stock Position Decreased by Lantern Wealth Advisors LLC - Markets Daily

Bristol Myers Squibb Company $BMY Shares Acquired by Brookstone Capital Management

The Call Bristol-Myers Squibb Bulls Got Right

Bristol Myers Squibb Reports Patient Death in MS CAR-T Therapy Trial, ETPharma

31,873 Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc.

Bristol Myers Squibb (NYSE:BMY) Cut to "Hold" at Zacks Research

Bristol Myers Squibb (NYSE:BMY) Downgraded by Zacks Research to Hold - Stock Observer

Tempus AI, Inc. $TEM Shares Bought by Washington Trust Advisors Inc. - Stock Observer

Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis - Daily Political

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as Buy by Needham & Company LLC - Markets Daily

Tempus AI's (TEM) "Buy" Rating Reiterated at Needham & Company LLC - Markets Daily

Bristol Myers Squibb Moves On Two Fronts: MS Cell Therapy Data And Tempus AI Expansion; Stock Down

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Fifth edition of MCADDI 2026 to be held at University of Hyderabad from October 25

Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals | Morningstar

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 | Morningstar

Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as "Buy" by Needham & Company LLC - Stock Observer

Tempus AI (NASDAQ:TEM) Earns Buy Rating from Needham & Company LLC - Stock Observer

Tempus AI (NASDAQ:TEM) Given "Buy" Rating at Needham & Company LLC - Stock Observer

Tempus AI's (TEM) "Buy" Rating Reaffirmed at Needham & Company LLC - Stock Observer

Tempus AI's (TEM) Buy Rating Reiterated at Needham & Company LLC - Stock Observer

Tempus AI (NASDAQ:TEM) Stock Keeps Buy Rating at Needham & Company LLC - Stock Observer

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions | Morningstar

3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street

NBT Bank N.A. Buys 52,930 Shares of Bristol Myers Squibb Company $BMY

What is Erste Group Bank's Estimate for BMY FY2027 Earnings? - Stock Observer

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Morningstar

Amgen Inc. $AMGN Shares Sold by Foster Victor Wealth Advisors LLC

Astellas Pharma (OTCMKTS:ALPMY) versus Bristol Myers Squibb (NYSE:BMY) Financial Analysis - Zolmax

Bristol Myers Squibb (BMY) Expected to Release Earnings on Thursday

Ovarian Cancer Pipeline 2026: Emerging Drugs, Regulatory Milestones, and Strategic Moves by Leading Players | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact | ABNewswire

Bristol Myers Squibb Company $BMY Shares Sold by SteelPeak Wealth LLC

RBC Capital Reaffirms Their Hold Rating on Sanofi (SNYNF)

RBC Capital Remains a Buy on Eli Lilly & Co (LLY)

Bristol Myers Squibb Company $BMY Stock Sold by Robeco Institutional Asset Management B.V. - Daily Political

Sumitomo Mitsui DS Asset Management Company Ltd Sells 21,624 Shares of Bristol Myers Squibb Company $BMY - Daily Political

NATCO launches Chemo drug in US

Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%

Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?

Bristol Myers Squibb Company (NYSE:BMY) Stock Has Average Target Price of $64.88 According to Analysts

Analysts' Recent Ratings Updates for Bristol Myers Squibb (BMY) - Stock Observer

Bristol Myers Squibb Company $BMY Stock: Assenagon Asset Management S.A. Raises Position

RBC Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)

AbbVie (ABBV) Receives a Buy from RBC Capital

Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data

Drugmakers seek to intervene in lawsuit challenging 340B pilot

AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?

Microsoft 365 Copilot vs Google Gemini Enterprise: 2026 Adoption, Productivity Gains and Real-World AI Deployments

Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch

Bristol Myers vs. Eli Lilly: Is BMY's Deep Valuation Discount Hiding an Opportunity?

Analyzing Milestone Pharmaceuticals (NASDAQ:MIST) and Bristol Myers Squibb (NYSE:BMY) - Zolmax

Rare prostate cancer histologies: detection, characteristics and treatment

USA Financial Formulas Makes New $919,000 Investment in Bristol Myers Squibb Company $BMY - Markets Daily

13,923 Shares in Bristol Myers Squibb Company $BMY Bought by USA Financial Formulas - Zolmax

Lupin Receives CDSCO Approval for Nivolumab Biosimilar in India, ETPharma

Birch Hill Investment Advisors LLC Acquires 160,411 Shares of Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Newly Purchased by New England Research & Management Inc.

Bristol Myers Squibb (NYSE:BMY) Stock Moved Up to "Strong-Buy" by The Goldman Sachs Group

Bristol Myers Squibb Company $BMY Stock Bought by Howard Capital Management LLC - Daily Political

Analysts Conflicted on These Healthcare Names: Perspective Therapeutics (CATX), Bristol-Myers Squibb (BMY) and Incyte (INCY)

RBC Capital Sticks to Its Buy Rating for Roche Holding AG (RHHVF)

Eli Lilly & Co (LLY) Receives a Buy from RBC Capital

RBC Capital Sticks to Their Hold Rating for Merck & Company (MRK)

RBC Capital Reaffirms Their Hold Rating on Pfizer (PFE)

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb's Rally Has Momentum, but Can Its New Drugs Justify More Upside?

Triasima Portfolio Management inc. Purchases New Stake in Bristol Myers Squibb Company $BMY

Iams Wealth Management LLC Acquires 24,964 Shares of Bristol Myers Squibb Company $BMY

How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors

Insitro's Virtual Human attracts $1.5B MASH deal with Astrazeneca

Bristol Myers Squibb Company $BMY Stock Sold by Chiron Capital Management LLC - Stock Observer

Bristol Myers Squibb Company $BMY Shares Sold by Viking Fund Management LLC

Bristol Myers Squibb Company $BMY Position Reduced by Fort Washington Investment Advisors Inc. OH

Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY) - Markets Daily

65,007 Shares in Bristol Myers Squibb Company $BMY Purchased by B.A. Schrock Wealth Management Inc. - Stock Observer

14,607 Shares in Bristol Myers Squibb Company $BMY Acquired by Sanders Morris Harris LLC - Daily Political

Stock Market Movers: Best and Worst Performers of 14 October 2026

Bristol Myers Squibb (NYSE:BMY) Shares Up 4% - What's Next?

Bristol Myers Squibb Company $BMY Shares Sold by Perpetual Ltd

Bristol-Myers Squibb Company Stock Live Price, Chart, Analysis, News & Forecast - Buy, Sell & Trade US Equities Today

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial

Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial

Renal Cancer Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire

Bristol Myers Squibb Company $BMY Shares Sold by Courier Capital LLC - Zolmax

Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run

BlackLine Honors Global Enterprise Leaders Transforming Financial Operations

Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Wells Fargo & Company - Daily Political

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Week ahead: Earnings bonanza, ECB decision & US inflation

Week ahead: Megacap tech and 1-in-3 Dow components set to report

Week ahead: Fed to hike 100bps into a recession?

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk